615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I

Single cell sequencing reveals the impact of low dose vs standard dose chemotherapy and infection on lymphocytes in pediatric AML

Comparative epidemiological analysis of hematological malignancies in adolescents and young adults AYA in the United States of America USA 1990–2021 with projections to 2040

Fusion transcript dynamics as predictor of optimal molecular response in core binding factor Acute Myeloid Leukemia

Acute Myeloid Leukemia mortality in u S older adults A 45 year nationwide analysis with forecasting through 2050

Predictors of early mortality in Acute Myeloid Leukemia A population based analysis using SEER data

Evolving use of blast percentage thresholds and classification systems in AML clinical trials 2022–2025 A data driven trend analysis

Cladribine cytarabine and venetoclax based regimens are associated with durable remissions in patients pts with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

The Impact  of the number of cytogenetic abnormalities on clinical outcomes in Acute Myeloid Leukemia with complex karyotype

Acute Myeloid Leukemia and sepsis related mortality in the United States U S older adults Nationwide trends and disparities over 25 years 1999 – 2023

Treatment responses and survival of newly diagnosed older or unfit patients pts with IDH1 2 mutated Acute Myeloid Leukemia AML An analysis of the MARROW consortium

Real world validation of ELN2024 and BEAT AML2024 risk stratification in patients with Acute Myeloid Leukemia unfit for intensive chemotherapy in a multicenter italian cohort

Dose adjusted treatment with venetoclax for 7 days and 5 azacitidine or decitabine in patients with Acute Myeloid Leukemia or higher risk myelodysplastic neoplasms

Behind the blood brain barrier Contemporary screening practice patterns and trends of central nervous system involvement in acute myeloid leukemia treated with intensive regimens and hypomethylating agent venetoclax

Clinical characteristics demographics and survival outcomes in newly diagnosed CUX1 mutated Acute Myeloid Leukemia

7 day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

7 day venetoclax combined with intensive chemotherapy as induction treatment in high risk newly diagnosed Acute Myeloid Leukemia

Characteristics and outcomes in Acute Myeloid Leukemia with Mecom rearrangement treated with hypomethylating agent plus venetoclax

Impact of obesity on survival outcomes in Acute Myeloid Leukemia patients treated with hypomethylating agents A retrospective multicenter cohort study using real world data

Real world practice patterns of IDH inhibitors and outcomes of on label IDH inhibitor use for Acute Myeloid Leukemia in the United States

Allogeneic hematopoietic stem cell transplantation in CR1 and continuous Chemotherapy plus FLT3 targeting inhibitor had comparable outcomes in FLT3 ITD mutated Acute Myeloid Leukemia with negative measurable residual disease

Optimizing ELN 2022 Developing and validating a dynamic prognostic model for AML using platelet change rates and MRD kinetics

The infection spectrum in newly diagnosed Acute Myeloid Leukemia patients treated with venetoclax based or conventional chemotherapy A real world retrospective study

Real world insights into ATRA based maintenance therapy and prognostic markers of relapse in acute promyelocytic leukemia

Clinical cytogenetic and molecular characteriszation of Mecom rearranged pediatric de novo Acute Myeloid Leukemia AML A retrospective cohort study of the international berlin frankfurt Muenster I BFM AML study group

Shifting treatment paradigms lead to improved overall survival in Acute Myeloid Leukemia Real world data from an integrated health system

Central nervous system relapse in acute promyelocytic leukemia in the arsenic era A case series and review of emerging evidence

Outcomes and cause specific mortality of AML in adults from Chile

Real world outcomes and a novel prognostic assessment model for high risk acute promyelocytic leukemia receiving all trans retinoid acid and arsenic trioxide dual induction based on lasso cox regression

Neutropenia infections and mortality across Acute Myeloid Leukemia induction strategies A single center retrospective study

The 10 minute targeted geriatric assessment 10 TaGA a 10 domain to one score tool predicts early death in intensively treated older AML patients First results from a multicenter study

Risk factors for disseminated intravascular coagulation in pediatric acute promyelocytic leukemia Insights from the cclg APL 2016 study